Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients

Abstract

A coordination complex having a physiologically acceptable pK a includes a metal and a biologically active agent. The pK a of the coordination complex is less than the pK a of the biologically active agent. A pharmaceutical solution for treating a patient includes a coordination complex and water, wherein the coordination complex is at least partially soluble in the water at physiological pH and in a therapeutically efficacious concentration. A method for treating a patient includes administering a pharmaceutical solution including a coordination complex and water to a patient in need of a biologically active agent.

1 . A metal coordination complex of a biologically active agent and a metal,
 wherein the biologically active agent is selected from the group consisting of: aliskiren, entacapone, ellagic acid, docetaxel, digitoxin, dideoxyadenosine, amprenavir, piroxicam, penciclovir, paclitaxel, omapatrilat, oseltamivir, lamotrigine, and penicillamine, and their derivatives.   
     
     
         2 . The complex of  claim 1 , wherein the metal is selected from: s-block metals, d-block metals, and p-block metals. 
     
     
         3 . A pharmaceutical composition comprising a complex of  claim 1  and a pharmaceutically acceptable excipient. 
     
     
         4 . A pharmaceutical composition comprising a complex of  claim 2  and a pharmaceutically acceptable excipient. 
     
     
         5 . A method of treating an indication, comprising administering the complex of  claim 1  to a patient in need of the biologically active agent for the indication. 
     
     
         6 . A method of treating an indication, comprising administering the pharmaceutical composition of  claim 3  to a patient in need of the biologically active agent for the indication. 
     
     
         7 . A coordination complex comprising a metal and a biologically active agent which is selected from the group consisting of anticonvulsants, antihypertensives, antineoplastic agents, antivirals, cardiac glycosides, medicaments for treating the immune system, movement disorder drugs for treating Parkinson's disease, and non-steroidal anti-inflammatory drugs. 
     
     
         8 . The complex of  claim 7 , wherein the metal is selected from the group consisting of: s-block metals, d-block metals, and p-block metals 
     
     
         9 . A pharmaceutical composition comprising a complex of  claim 7  and a pharmaceutically acceptable excipient. 
     
     
         10 . A method for treating hypertension, comprising: administering the complex of  claim 7  to a patient in need of the biologically active agent. 
     
     
         11 . A method for treating cancer comprising: administering the complex of  claim 7  to a patient in need of the biologically active agent. 
     
     
         12 . A method for treating a viral infection, comprising: administering the complex of  claim 7  to a patient in need of the biologically active agent. 
     
     
         13 . A method for treating Parkinson's disease, comprising: administering the complex of  claim 7  to a patient in need of the biologically active agent. 
     
     
         14 . A method for treating an immune system disorder, comprising:
 administering the complex of  claim 7  to a patient in need of the biologically active agent.   
     
     
         15 . A method for treating pain or inflammation, comprising: administering the composition of  claim 7  to a patient in need of the biologically active agent. 
     
     
         16 . A method for treating the cardiovascular system comprising: administering the composition of  claim 7  to a patient in need of the biologically active agent. 
     
     
         17 . The complex of  claim 2 , wherein the metal is selected from the group consisting of magnesium, calcium, strontium, iron, zinc, and nickel. 
     
     
         18 . The complex of  claim 1 , wherein a pK a  of the coordination complex is less than the pK a  of the biologically active agent. 
     
     
         19 . The complex of  claim 1  further comprising a buffering ligand. 
     
     
         20 . The complex of claim  24 , wherein the buffering ligand is selected from the group consisting of an amino acid, a peptide, a carbohydrate, and a Good's buffer.